Novo Nordisk to license experimental GLP-1 pill from China's Hengrui - Reuters
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOMWlFaF9yQXl1azczbExDallSSXZxUGd6aTJXVkw5Y3ZiOWRLdTBVcUo1bDl6TEdXNjBPV0hmNEdfaXRhQkJjVHNHTHVDdmhoSUZUT294T3VGbndYN3dNY3I3SXdJNzN6RDlDYUl2M1RZQW9PdENzRUhjWE1tZVk5ZjduZ04xY0VrX1IxS3duN1Faajk1dDFEdDktT2xxZzBPb1cySlZfRlI2SXJCV2dmR2xjc2U0M3IzSU1LbGZmaw?oc=5" target="_blank">Novo Nordisk to license experimental GLP-1 pill from China's Hengrui</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Lilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMUS FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMPatients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study - Reuters
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Reuters
September 30, 2026 at 09:57 AMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AM